FDA Landmark Study on the risks of Birth control such as Yaz, Yasmin, Ocella, Nuvaring and Ortho Evra
Breaking news was released from the FDA this morning concerning a landmark study of the risk of arterial and venous cardiovascular complications caused by Yaz, Yasmin and Ocella. Until now, there was limited data available regarding the risk of venus thromboembolism (VTE) (deep venous thrombosis [DVT] and pulmonary embolism [PE]) in combined hormonal contraceptives (CHCs), […]
